Third Rock Ventures IV, L.P. - Jul 30, 2024 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
10%+ Owner
Signature
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.
Stock symbol
TNGX
Transactions as of
Jul 30, 2024
Transactions value $
-$2,316,494
Form type
4
Date filed
8/1/2024, 05:51 PM
Previous filing
Jul 30, 2024
Next filing
Aug 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Sale -$931K -95K -0.54% $9.80 17.6M Jul 30, 2024 Direct F1, F2
transaction TNGX Common Stock Sale -$993K -100K -0.57% $9.93 17.5M Jul 31, 2024 Direct F2, F3
transaction TNGX Common Stock Sale -$392K -40K -0.23% $9.80 17.5M Aug 1, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $9.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2 These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.84 to $10.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).